AbbVie (ABBV) announced that a new 6-month 45mg LUPRON DEPOT, or leuprolide acetate for extended-release injectable suspension, strength has received Health Canada approval for the treatment of advanced prostate cancer. LUPRON DEPOT is now available in four dosing options.
LUPRON DEPOT is a hormonal medication approved by Health Canada for various conditions including advanced prostate cancer, endometriosis, uterine fibroids, and central precocious puberty. It is a synthetic gonadotropin-releasing hormone analog. LUPRON DEPOT was initially approved by Health Canada for advanced prostate cancer in 1989.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
April 10, 2026 16:21 ET Inflation data from the U.S. was the main data event this week as the conflict in the Middle East continue. The minutes of the latest Fed policy session and the survey data on the services sector also made headlines. In Europe, manufacturing orders data from Germany was in focus. Price data from China drew attention in Asia.